Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDRD2HTR1BHTR1DHTR1F
The experimentally established mechanism targets of Malic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 9/20 | 0.55 |
| ▸ | HTR1A | P08908 | 16/20 | 0.55 |
| ▸ | DRD3 | P35462 | 8/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1752535 | 0.84 | HTR1A (0.71) | HTR1ADRD2DRD3 | |
| SCHEMBL5141708 | 0.84 | HTR1A (0.71) | HTR1ADRD2DRD3 | |
| Fumaric Acid SCHEMBL5906537 | 0.83 | HTR1A (0.62) | HTR1ADRD2DRD3 | |
| Maleic Acid SCHEMBL5906535 | 0.83 | HTR1A (0.62) | HTR1ADRD2DRD3 | |
| Sumanirole SCHEMBL6269816 | 0.72 | HTR1A (1.00) | HTR1ADRD2DRD3 | |
| Sumanirole SCHEMBL154412 | 0.72 | HTR1A (1.00) | HTR1ADRD2DRD3 | |
| Sumanirole SCHEMBL7046470 | 0.72 | HTR1A (0.82) | HTR1ADRD2DRD3 | |
| Sumanirole SCHEMBL5906552 | 0.71 | HTR1A (0.97) | HTR1ADRD2DRD3 | |
| SCHEMBL5424144 | 0.65 | HTR1A (0.70) | HTR1ADRD2DRD3 | |
| SCHEMBL7344870 | 0.63 | HTR1A (1.00) | HTR1ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214823-A1 | Method of treating sexual disturbances | PHARMACIA & UPJOHN COMPANY | 2004-10-28 | — | — | US | claimed |
| US-20030013710-A1 | Method of treating sexual disturbances | MCCALL ROBERT B (US) | 2003-01-16 | — | — | US | claimed |
| US-20030004152-A1 | Method of treating sexual disturbances | MCCALL ROBERT B (US) | 2003-01-02 | — | — | US | claimed |
| US-20020198187-A1 | Method of treating sexual disturbances | MCCALL ROBERT B (US) | 2002-12-26 | — | — | US | claimed |
| US-20020107247-A1 | Method of treating sexual disturbances | MCCALL ROBERT B (US) | 2002-08-08 | — | — | US | claimed |
| US-6921771-B2 | Method of treating sexual disturbances | PHARMACIA & UPJOHN COMPANY (US) | 2005-07-26 | — | — | US | disclosed |
| US-6903127-B2 | Method of treating sexual disturbances | PHARMACIA & UPJOHN COMPANY (US) | 2005-06-07 | — | — | US | disclosed |
| US-6890945-B2 | Method of treating sexual disturbances | PHARMACIA & UPJOHN COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| US-20040214826-A1 | Method of treating sexual disturbances | PHARMACIA & UPJOHN COMPANY | 2004-10-28 | — | — | US | disclosed |
| US-20040214825-A1 | treating sexual disorders using (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione | PHARMACIA & UPJOHN COMPANY | 2004-10-28 | — | — | US | disclosed |
| US-20040214824-A1 | Method of treating sexual disturbances | PHARMACIA & UPJOHN COMPANY | 2004-10-28 | — | — | US | disclosed |
| US-20040214823-A1 | Method of treating sexual disturbances | PHARMACIA & UPJOHN COMPANY | 2004-10-28 | — | — | US | disclosed |
| US-6809112-B2 | ADMINISTERING A SEXUALLY THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND HAVING THE FORMULA LIKE (5R)-5-(METHYLAMINO)-5,6-DIHYDRO-4H-IMIDAZO(4,5,1-IJ)QUINOLINE-2(1H)-THIONE | PHARMACIA & UPJOHN COMPANY | 2004-10-26 | — | — | US | disclosed |
| US-20040142937-A1 | Use of heterocyclic amine-type compounds as neuroprotective agents | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| US-20030013710-A1 | Method of treating sexual disturbances | MCCALL ROBERT B (US) | 2003-01-16 | — | — | US | disclosed |
| US-20030004152-A1 | Method of treating sexual disturbances | MCCALL ROBERT B (US) | 2003-01-02 | — | — | US | disclosed |
| US-20020198187-A1 | Method of treating sexual disturbances | MCCALL ROBERT B (US) | 2002-12-26 | — | — | US | disclosed |
| US-6455564-B1 | ORAL ADMINISTRATION OF (5R)-(METHYLAMINO)-5,6-DIHYDRO-4H-IMIDAZO(4,5,1-IJ)QUINOLIN-2( '1H)-ONE OR -THIONE | PHARMACIA & UPJOHN COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-20020107247-A1 | Method of treating sexual disturbances | MCCALL ROBERT B (US) | 2002-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214824-A1 | Method of treating sexual disturbances | CYP19A1, CYP17A1, CYP21A2 | DRD2 332/4885HTR1A 43/4885DRD3 295/4885 |
| US-20040214825-A1 | treating sexual disorders using (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione | SULT1A1, CYP19A1, SHBG | DRD2 302/4885HTR1A 46/4885DRD3 496/4885 |
| US-20040214826-A1 | Method of treating sexual disturbances | CYP19A1, CYP17A1, CYP21A2 | DRD2 332/4885HTR1A 43/4885DRD3 295/4885 |
| US-20030004152-A1 | Method of treating sexual disturbances | CYP19A1, CYP17A1, CYP21A2 | DRD2 332/4885HTR1A 43/4885DRD3 295/4885 |
| US-20040142937-A1 | Use of heterocyclic amine-type compounds as neuroprotective agents | NLN, GAP43, BDNF | DRD2 238/4885HTR1A 113/4885DRD3 582/4885 |
| US-20020107247-A1 | Method of treating sexual disturbances | CYP19A1, CYP17A1, CYP21A2 | DRD2 332/4885HTR1A 43/4885DRD3 295/4885 |
| US-20030013710-A1 | Method of treating sexual disturbances | CYP19A1, CYP17A1, CYP21A2 | DRD2 332/4885HTR1A 43/4885DRD3 295/4885 |
| US-20020198187-A1 | Method of treating sexual disturbances | CYP19A1, CYP17A1, CYP21A2 | DRD2 332/4885HTR1A 43/4885DRD3 295/4885 |
| US-20040214823-A1 | Method of treating sexual disturbances | CYP19A1, CYP17A1, CYP21A2 | DRD2 332/4885HTR1A 43/4885DRD3 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.